
- Review studies done by our group in Missouri and Michigan—which have uncovered this overlooked form of hypoglycemia (FEEHD).
- Review recent literature proposing non-fasting for lipid testing.
- Discuss the proposed “Population-based FEEHD Survey”

Saleh Aldasouqi, MD, FACE, ECNU
Professor of Medicine
Chief, Division of Endocrinology
Department of Medicine, MSU College of Human Medicine

Saleh Aldasouqi received his MBBS (MD) degree from Jordan University School of Medicine. He completed Internal Medicine residency at Hurley Medical Center (Co-Chief Resident) in Flint, MI (MSU), followed by Endocrinology fellowship (Chief Fellow) at Indiana University in Indianapolis, IN. He has worked in both private practice and academia, in the Kingdom of Saudi Arabia (KSA) and the USA.

Dr. Aldasouqi’s research areas include: Hypoglycemia Due to Fasting for Lipid Labs (FEEHD); Diagnosis and Screening of Diabetes; The Role of US in Graves’ Disease. The FEEHD research is a novel series of studies pioneered by Dr. Aldasouqi, which began with a pilot study in Missouri in 2009 published in Diabetes Care in 2011. Subsequent studies followed by targeting the prevalence and implications of FEEHD in clinical practice. The FEEHD research has alerted clinicians about the risk of hypoglycemia in patients with diabetes who fast for lipid labs. Dr. Aldasouqi’s studies have been recently cited in reviews and guidelines proposing non-fasting lipid testing by investigators in the US and Canada.